EXAS

NEUTRALM&A

Exact Sciences Corporation

2026-02-26

Price

$103.25

-0.02%

Score12.0Top Tier

Signals5/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.9xvs 20d avg

Analysis

EXAS is currently a late-stage Merger Arbitrage play, trading at $103.25 against a confirmed $105.00/share all-cash acquisition by Abbott Laboratories (ABT). The 'Quiet Storm' and 'Steady Climb' signals, combined with an ultra-low 2.7% realized volatility, confirm the stock is effectively 'pinned' to the deal price following the February 20, 2026 shareholder approval. With HSR regulatory waiting periods reportedly expired in late 2025, the remaining ~1.7% spread represents the time-value discount before the deal formally closes. In a RISK_ON regime, this acts as a high-quality cash substitute rather than a growth trade.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKBARGAIN HUNTER

Key Takeaways

Deal Certainty: Shareholders approved the merger on Feb 20, 2026; HSR hurdles are cleared.
The Trade: A low-risk arbitrage spread of $1.75 (~1.7%) remains until the deal closes.
Signal Context: Technical signals are flagging the steady, low-volatility grind toward the $105 buyout price, not organic momentum.

← Back to 2026-02-26 View Full EXAS History →Yahoo Finance &nearr;